A prospective study of orelabrutinib plus obinutuzumab (O2) in treatment-naïve marginal zone lymphoma
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Obinutuzumab (Primary) ; Orelabrutinib (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 20 Jan 2025 New trial record